Al B. Benson

72.8k total citations · 13 hit papers
492 papers, 31.0k citations indexed

About

Al B. Benson is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Al B. Benson has authored 492 papers receiving a total of 31.0k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Oncology, 133 papers in Surgery and 133 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Al B. Benson's work include Colorectal Cancer Treatments and Studies (150 papers), Gastric Cancer Management and Outcomes (89 papers) and Pancreatic and Hepatic Oncology Research (80 papers). Al B. Benson is often cited by papers focused on Colorectal Cancer Treatments and Studies (150 papers), Gastric Cancer Management and Outcomes (89 papers) and Pancreatic and Hepatic Oncology Research (80 papers). Al B. Benson collaborates with scholars based in United States, Canada and France. Al B. Benson's co-authors include Paul J. Catalano, Peter J. O’Dwyer, Mary F. Mulcahy, Daniel G. Haller, Steven R. Alberts, Edith P. Mitchell, Robert J. Mayer, Neal J. Meropol, Riad Salem and John S. Macdonald and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Al B. Benson

476 papers receiving 30.3k citations

Hit Papers

Bevacizumab in Combination With Oxaliplatin, Fluorouracil... 2002 2026 2010 2018 2007 2005 2004 2014 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
    2007 1.7k citations Bruce J. Giantonio, Paul J. Catalano et al. Journal of Clinical Oncology profile →
  2. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
    2005 1.4k citations Al B. Benson et al. Journal of Clinical Oncology profile →
  3. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
    2004 1.1k citations Al B. Benson, Patrick J. Flynn et al. Journal of Clinical Oncology profile →
  4. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2014 762 citations Al B. Benson et al. Journal of Clinical Oncology profile →
  5. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes
    2009 740 citations Riad Salem, Robert J. Lewandowski et al. Gastroenterology profile →
  6. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
    2011 604 citations Patrick J. Loehrer, Yang Feng et al. Journal of Clinical Oncology profile →
  7. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
    2002 602 citations Paul J. Catalano, Al B. Benson et al. Journal of Clinical Oncology profile →
  8. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
    2008 527 citations William F. Regine, Ross A. Abrams et al. profile →
  9. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium
    2007 511 citations Riad Salem, Al B. Benson et al. profile →
  10. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
    2016 433 citations Riad Salem, Andrew C. Gordon et al. Gastroenterology profile →
  11. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin
    2012 370 citations Jaffer A. Ajani, Al B. Benson et al. Journal of Clinical Oncology profile →
  12. Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies
    2019 230 citations Al B. Benson, Sheetal Kircher et al. profile →
  13. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
    2022 125 citations Pamela L. Kunz, Noah Graham et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Al B. Benson United States 94 18.9k 8.7k 8.7k 5.8k 5.5k 492 31.0k
Leonard B. Saltz United States 105 28.0k 1.5× 9.6k 1.1× 10.3k 1.2× 5.5k 0.9× 4.2k 0.8× 544 38.3k
Michel Ducreux France 91 26.0k 1.4× 10.7k 1.2× 11.8k 1.4× 8.7k 1.5× 5.5k 1.0× 628 38.9k
Malcolm J. Moore Canada 72 25.0k 1.3× 10.6k 1.2× 9.5k 1.1× 2.9k 0.5× 7.3k 1.3× 358 37.0k
Jean‐Luc Raoul France 56 12.1k 0.6× 5.8k 0.7× 5.9k 0.7× 11.6k 2.0× 4.8k 0.9× 342 26.4k
Olivier Bouché France 60 18.6k 1.0× 9.5k 1.1× 8.0k 0.9× 3.0k 0.5× 4.5k 0.8× 418 25.3k
Filippo de Braud Italy 74 17.9k 0.9× 8.8k 1.0× 5.6k 0.6× 2.5k 0.4× 3.7k 0.7× 754 26.7k
Timothy M. Pawlik United States 87 14.9k 0.8× 8.7k 1.0× 13.5k 1.6× 9.0k 1.6× 3.1k 0.6× 689 28.9k
Armando Santoro Italy 87 17.8k 0.9× 13.8k 1.6× 3.8k 0.4× 5.4k 0.9× 3.8k 0.7× 924 34.7k
Bengt Glimelius Sweden 92 30.4k 1.6× 9.9k 1.1× 18.0k 2.1× 3.5k 0.6× 3.3k 0.6× 700 41.7k
Janet Dancey United States 68 19.9k 1.0× 15.4k 1.8× 5.5k 0.6× 3.2k 0.5× 6.2k 1.1× 205 38.3k

Countries citing papers authored by Al B. Benson

Since Specialization
Citations

This map shows the geographic impact of Al B. Benson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Al B. Benson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Al B. Benson more than expected).

Fields of papers citing papers by Al B. Benson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Al B. Benson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Al B. Benson. The network helps show where Al B. Benson may publish in the future.

Co-authorship network of co-authors of Al B. Benson

This figure shows the co-authorship network connecting the top 25 collaborators of Al B. Benson. A scholar is included among the top collaborators of Al B. Benson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Al B. Benson. Al B. Benson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gordon, Andrew C., Sheetal Kircher, Al B. Benson, et al.. (2024). Yttrium-90 Radiation Segmentectomy for Treatment of Neuroendocrine Liver Metastases. Journal of Vascular and Interventional Radiology. 36(2). 293–300. 1 indexed citations
3.
Kircher, Sheetal, et al.. (2024). Oncologic drug repository programs in the United States: a review and comparison. Health Affairs Scholar. 2(3). qxae031–qxae031. 1 indexed citations
4.
McGarrah, Patrick W., Joleen M. Hubbard, Paul J. Novotny, et al.. (2023). Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control. 30. 2915603095–2915603095. 3 indexed citations
5.
Kunz, Pamela L., Noah Graham, Paul J. Catalano, et al.. (2022). Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology. 41(7). 1359–1369. 125 indexed citations breakdown →
6.
Huynh, Lynn, et al.. (2017). Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics. 20(9). 945–951. 7 indexed citations
7.
Benson, Al B., Igor Kišš, John Bridgewater, et al.. (2016). BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer. Clinical Cancer Research. 22(20). 5058–5067. 17 indexed citations
8.
Bartley, Angela N., M. Kay Washington, Christina B. Ventura, et al.. (2016). HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal of Clinical Pathology. 146(6). 647–669. 45 indexed citations
9.
Nimeiri, Halla, et al.. (2014). A feasibility study of dignity therapy in patients with stage IV colorectal cancer actively receiving second-line chemotherapy. The Journal of Community and Supportive Oncology. 12(12). 446–453. 24 indexed citations
10.
Meropol, Neal J., Brian L. Egleston, Joanne S. Buzaglo, et al.. (2013). A Web‐based communication aid for patients with cancer. Cancer. 119(7). 1437–1445. 34 indexed citations
11.
Bates, David O., Paul J. Catalano, Kirsty E. Symonds, et al.. (2012). Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab. Clinical Cancer Research. 18(22). 6384–6391. 54 indexed citations
12.
Vergo, Maxwell T. & Al B. Benson. (2012). Point: Treating Stage II Colon Cancer: The Quest for Personalized Adjuvant Care. Journal of the National Comprehensive Cancer Network. 10(11). 1370–1374. 2 indexed citations
13.
Ogino, Shuji, Kaori Shima, Jeffrey A. Meyerhardt, et al.. (2011). Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clinical Cancer Research. 18(3). 890–900. 207 indexed citations
14.
Loehrer, Patrick J., Yang Feng, Higinia R. Cárdenes, et al.. (2011). Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 29(31). 4105–4112. 604 indexed citations breakdown →
15.
Memon, Khairuddin, Robert J. Lewandowski, Laura Kulik, et al.. (2011). Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology. 55(5). 1432–1442. 56 indexed citations
16.
Sætrom, Pål, Jacob Biesinger, David Smith, et al.. (2009). A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis. Cancer Research. 69(18). 7459–7465. 118 indexed citations
17.
Farrell, James J., Hany Elsaleh, M. López García, et al.. (2008). Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology. 136(1). 187–195. 331 indexed citations
18.
Benson, Al B.. (2006). Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network. 4(8). 728–728. 38 indexed citations
19.
Engstrom, P, Al B. Benson, Adam J. Cohen, et al.. (1996). NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.. PubMed. 10(11 Suppl). 140–75. 50 indexed citations
20.
Gradishar, William J., et al.. (1995). A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. Investigational New Drugs. 13(2). 171–174. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard B. Saltz Breakdown of academic impact, for papers by Michel Ducreux Breakdown of academic impact, for papers by Malcolm J. Moore Breakdown of academic impact, for papers by Jean‐Luc Raoul Breakdown of academic impact, for papers by Olivier Bouché Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Timothy M. Pawlik Breakdown of academic impact, for papers by Armando Santoro Breakdown of academic impact, for papers by Bengt Glimelius Breakdown of academic impact, for papers by Janet Dancey
Rankless by CCL
2026